|
End-of-day quote
Shanghai S.E.
26/10/2026
|
5-day change | 1st Jan Change | ||
| 24.33 CNY | +0.16% |
|
-0.98% | -13.11% |
Company Valuation: Mayinglong Pharmaceutical Group Co., LTD.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 10,423 | 11,255 | 12,070 | 10,488 | - | - |
| Change | - | 7.98% | 7.24% | -13.11% | - | - |
| Enterprise Value (EV) | 10,423 | 11,255 | 12,070 | 10,488 | 10,488 | 10,488 |
| Change | - | 7.98% | 7.24% | -13.11% | 0% | 0% |
| P/E | - | 21.2x | 20.7x | 15.7x | 14.2x | 12.8x |
| PBR | - | 2.77x | 2.76x | 2.21x | 1.91x | 1.65x |
| PEG | - | - | 2.12x | 1.1x | 1.3x | 1.2x |
| Capitalization / Revenue | 3.32x | 3.02x | 3.12x | 2.5x | 2.28x | 2.11x |
| EV / Revenue | 0x | 0x | 0x | 2.5x | 2.28x | 2.11x |
| EV / EBITDA | - | 0x | 0x | 12.6x | 11.3x | 10.3x |
| EV / EBIT | - | 0x | 0x | 13.1x | 11.8x | 10.8x |
| EV / FCF | - | 0x | - | 10.6x | 10.4x | 9.55x |
| FCF Yield | - | 2.62% | - | 9.45% | 9.6% | 10.5% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | 1.23 | 1.35 | 1.545 | 1.715 | 1.9 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,137 | 3,728 | 3,867 | 4,198 | 4,606 | 4,980 |
| EBITDA 1 | - | 686.7 | 791.2 | 834 | 926.5 | 1,014 |
| EBIT 1 | - | 666.8 | 719.9 | 801 | 886.5 | 975 |
| Net income 1 | 443.3 | 528.1 | 581.5 | 667.5 | 739.5 | 819 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 24.18 | 26.11 | 28.00 | 24.33 | 24.33 | 24.33 |
| Nbr of stocks (in thousands) | 4,31,054 | 4,31,054 | 4,31,054 | 4,31,054 | - | - |
| Announcement Date | 12/04/24 | 02/04/25 | 24/04/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 15.72x | - | - | - | 156.97Cr | ||
| 37.06x | 13.1x | 27.8x | 0.54% | 1,13500Cr | ||
| 38.61x | 6.49x | 18.27x | 2.02% | 64TCr | ||
| 36.46x | 8.38x | 17.33x | 2.41% | 50TCr | ||
| 20.87x | 5.11x | 12.73x | 2.56% | 38TCr | ||
| 105.89x | 5.92x | 25.41x | 2.34% | 36TCr | ||
| 21.76x | 5.68x | 13.94x | 2.81% | 29TCr | ||
| 22.43x | 4.53x | 12.94x | 1.95% | 27TCr | ||
| 27.87x | 7.16x | 12.81x | 2.3% | 24TCr | ||
| -45.48x | 6.98x | 27.06x | 2.11% | 19TCr | ||
| Average | 28.12x | 7.04x | 18.70x | 2.12% | 40.05TCr | |
| Weighted average by Cap. | 35.22x | 8.29x | 20.40x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 600993 Stock
- Valuation Mayinglong Pharmaceutical Group Co., LTD.
Select your edition
All financial news and data tailored to specific country editions
















